Pharmacotherapy for anorexia nervosa and bulimia nervosa;Pharmakotherapie von Anorexia nervosa und Bulimia nervosa: State of the Art

Fortschritte der Neurologie Psychiatrie

Volumn 80, Issue 1, 2012, Pages 9-16

  Greetfeld, M ^a   Cuntz, U ^a   Voderholzer, Ulrich ^a,b  

^a Schon Klinik Roseneck   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

anorexia nervosa; bulimia nervosa; eating disorders; pharmacotherapy

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT;

ANOREXIA NERVOSA; ARTICLE; BULIMIA; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERACTIVITY; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; RUMINATION; WEIGHT GAIN;

ANOREXIA NERVOSA; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BULIMIA NERVOSA; HUMANS; SEROTONIN UPTAKE INHIBITORS; WEIGHT GAIN;

EID: 84855781603     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0031-1281845     Document Type: Article

References (74)

1. WHO Internationale Klassifikation psychischer Strungen. ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien. 7. Aufl Bern Huber: 2009
2. Practice guideline for the treatment of patients with eating disorders. 3rd edition American Psychiatric Association (APA): 2006
3. S3-Leitlinie Diagnostik und Therapie der Essstrungen Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): 2010
4. Currin L, Schmidt U, Treasure J et al. Time trends in eating disorder incidence. Br J Psychiatry: 2005; 186 132 135 (Pubitemid 40193782)
5. Fichter MM, Quadflieg N, Hedlund S. Twelve-year course and outcome predictors of anorexia nervosa. Int J Eat Disord: 2006; 39 87 100 (Pubitemid 43201596)
6. Fichter MM, Quadflieg N, Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: relevance for nosology and diagnostic criteria. Int J Eat Disord: 2008; 41 577 586
7. Voderholzer U, Hohagen F. Essstrungen (ICD-10 F5). In: Therapie psychischer Erkrankungen: State of the Art 2010/2011 6. Aufl Urban & Fischer Verlag/Elsevier GmbH: 2010; 289 302
8. Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav: 2008; 94 121 135 (Pubitemid 351506510)
9. Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol: 2011; 18 1 19
10. Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol: 2011; 25 1 14
11. Eating disorders: full guideline (CG9). National Institute for Health and Clinical Excellence (NICE): 2004
12. Fassino S, Piero A, Tomba E et al. Factors associated with dropout from treatment for eating disorders: a comprehensive literature review. BMC Psychiatry: 2009; 9 67 67
13. Biederman J, Herzog DB, Rivinus TM et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, plazebo-controlled study. JClin Psychopharmacol: 1985; 5 10 16 (Pubitemid 15126295)
14. Halmi KA, Eckert E, LaDu TJ et al. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry: 1986; 43 177 181
15. Attia E, Haiman C, Walsh BT et al. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry: 1998; 155 548 551 (Pubitemid 28207453)
16. Fassino S, Leombruni P, Daga G et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol: 2002; 12 453 459
17. Walsh BT, Kaplan AS, Attia E et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA: 2006; 295 2605 2612 (Pubitemid 43882335)
18. Santonastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol: 2001; 11 143 150 (Pubitemid 32588485)
19. Strober M, Freeman R, DeAntonio M et al. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal followup and comparison with historical controls. Psychopharmacol Bull: 1997; 33 425 431
20. Ruggiero GM, Mauri MC, Omboni AC et al. Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up. Prog Neuropsychopharmacol Biol Psychiatry: 2003; 27 425 430 (Pubitemid 36403733)
21. Kaye WH, Nagata T, Weltzin TE et al. Double-blind plazebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry: 2001; 49 644 652 (Pubitemid 32289359)
22. Ruggiero GM, Laini V, Mauri MC et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry: 2001; 25 1049 1059 (Pubitemid 32769997)
23. Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J: 1980; 56 01 79 85 (Pubitemid 10119391)
24. Jaafar NR, Daud TI, Rahman FN et al. Mirtazapine for anorexia nervosa with depression. Aust N Z J Psychiatry: 2007; 41 768 769 (Pubitemid 47261156)
25. Safer DL, Darcy AM, Lock J. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: A case report. Int J Eat Disord: 2011; 44 178 181
26. Hrdlicka M, Beranova I, Zamecnikova R et al. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study. Eur Child Adolesc Psychiatry: 2008; 17 187 189
27. Claudino AM, Hay P, Lima MS et al. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev: 2006; CD004365
28. Godart NT, Perdereau F, Rein Z et al. Comorbidity studies of eating disorders and mood disorders. Critical review of the literature. J Affect Disord: 2007; 97 37 49
29. Mischoulon D, Eddy KT, Keshaviah A et al. Depression and eating disorders: Treatment and course. J Affect Disord: 2010
30. Ricca V, Mannucci E, Paionni A et al. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eat Weight Disord: 1999; 4 10 14
31. Meehan KG, Loeb KL, Roberto CA et al. Mood change during weight restoration in patients with anorexia nervosa. Int J Eat Disord: 2006; 39 587 589 (Pubitemid 44621812)
32. Barbarich NC, McConaha CW, Gaskill J et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry: 2004; 65 1480 1482
33. Boachie A, Goldfield GS, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord: 2003; 33 98 103 (Pubitemid 36020247)
34. Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord: 2002; 32 146 154 (Pubitemid 34848184)
35. Bissada H, Tasca GA, Barber AM et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, plazebo-controlled trial. Am J Psychiatry: 2008; 165 1281 1288
36. Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology: 2007; 32 402 406 (Pubitemid 46617784)
37. Mondraty N, Birmingham CL, Touyz S et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry: 2005; 13 72 75 (Pubitemid 40514990)
38. Malina A, Gaskill J, McConaha C et al. Olanzapine treatment of anorexia nervosa: a retrospective study. Int J Eat Disord: 2003; 33 234 237 (Pubitemid 36249838)
39. Weizman A, Tyano S, Wijsenbeek H et al. Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychother Psychosom: 1985; 43 136 140 (Pubitemid 15101768)
40. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind plazebo-controlled cross-over study. Acta Psychiatr Scand: 1982; 66 445 450 (Pubitemid 13242401)
41. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind plazebo-controlled study with sulpiride. Br J Psychiatry: 1984; 144 288 292 (Pubitemid 14159403)
42. Cassano GB, Miniati M, Pini S et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Disord: 2003; 33 172 177 (Pubitemid 36249830)
43. Bosanac P, Kurlender S, Norman T et al. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol: 2007; 22 223 230 (Pubitemid 46939279)
44. Powers PS, Bannon Y, Eubanks R et al. Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord: 2007; 40 21 26 (Pubitemid 44936523)
45. Court A, Mulder C, Kerr M et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res: 2010; 44 1027 1034
46. Trunko ME, Schwartz TA, Duvvuri V et al. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord: 2011; 44 269 275
47. Gross H, Ebert MH, Faden VB et al. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol: 1983; 3 165 171 (Pubitemid 13071193)
48. Gross HA, Ebert MH, Faden VB et al. A double-blind controlled trial of lithium carbonate primary anorexia nervosa. J Clin Psychopharmacol: 1981; 1 376 381 (Pubitemid 12189861)
49. Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord: 1994; 15 251 255 (Pubitemid 24099827)
50. Pope Jr. HG, Hudson JI, Jonas JM et al. Bulimia treated with imipramine: a plazebo-controlled, double-blind study. Am J Psychiatry: 1983; 140 554 558 (Pubitemid 13080522)
51. Barlow J, Blouin J, Blouin A et al. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry: 1988; 33 129 133
52. Sabine EJ, Yonace A, Farrington AJ et al. Bulimia nervosa: a plazebo controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol: 1983; 15 02 195S 202S (Pubitemid 13094494)
53. Goldstein DJ, Wilson MG, Thompson VL et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry: 1995; 166 660 666
54. Fluoxetine Bulimia Nervosa Collaborative Study Group Fluoxetine in the treatment of bulimia nervosa. A multicenter, plazebo-controlled, double-blind trial. Arch Gen Psychiatry: 1992; 49 139 147
55. Fichter MM, Leibl K, Rief W et al. Fluoxetine versus plazebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry: 1991; 24 1 7
56. Fichter MM, Leibl C, Kruger R et al. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry: 1997; 30 85 92 (Pubitemid 27232493)
57. Milano W, Petrella C, Sabatino C et al. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther: 2004; 21 232 237 (Pubitemid 39524900)
58. Capasso A, Petrella C, Milano W. Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders. Curr Clin Pharmacol: 2009; 4 78 83
59. Pope Jr. HG, Keck Jr. PE, McElroy SL et al. A plazebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol: 1989; 9 254 259 (Pubitemid 19198959)
60. Bacaltchuk J, Hay P. Antidepressants versus plazebo for people with bulimia nervosa. Cochrane Database Syst Rev: 2003; CD003391
61. Carruba MO, Cuzzolaro M, Riva L et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a plazebo-controlled trial. Int Clin Psychopharmacol: 2001; 16 27 32 (Pubitemid 32042838)
62. Horne RL, Ferguson JM, Pope Jr. HG et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry: 1988; 49 262 266
63. Romano SJ, Halmi KA, Sarkar NP et al. A plazebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry: 2002; 159 96 102 (Pubitemid 41070733)
64. Schmidt U, Cooper PJ, Essers H et al. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, plazebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy. J Clin Psychopharmacol: 2004; 24 549 552 (Pubitemid 39274213)
65. Sysko R, Sha N, Wang Y et al. Early response to antidepressant treatment in bulimia nervosa. Psychol Med: 2010; 40 999 1005
66. Goldstein DJ, Wilson MG, Ascroft RC et al. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord: 1999; 25 19 27 (Pubitemid 29031305)
67. Agras WS, Rossiter EM, Arnow B et al. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry: 1992; 149 82 87
68. Goldbloom DS, Olmsted M, Davis R et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther: 1997; 35 803 811 (Pubitemid 27390079)
69. Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev: 2001; CD003385
70. Nickel C, Tritt K, Muehlbacher M et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, plazebo-controlled trial. Int J Eat Disord: 2005; 38 295 300 (Pubitemid 41785844)
71. Hedges DW, Reimherr FW, Hoopes SP et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, plazebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry: 2003; 64 1449 1454 (Pubitemid 41270103)
72. Hoopes SP, Reimherr FW, Hedges DW et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, plazebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry: 2003; 64 1335 1341 (Pubitemid 37490239)
73. Faris PL, Kim SW, Meller WH et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet: 2000; 355 792 797 (Pubitemid 30128819)
74. Hsu LK, Clement L, Santhouse R et al. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis: 1991; 179 351 355